
CVRx, Inc.
CVRXNASDAQHealthcareMedical - Devices
最新数据
US$3.055
+US$0.215 · +7.57%
CVRX公司概览
盘中时间采用ET。市场数据可能有所延迟。
GoAI 研究快照
简明呈现最新可用的模型信息。
GoAI评分
Hold
Wait — insufficient conviction to act
估值
74
Undervalued
动量
22
Weakening
情绪
49
Mixed
风险韧性
33
High Risk
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
人工智能生成的上下文仅供参考,并非投资建议。
公司概况
公司网站CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories. Incorporated in 2000, CVRx, Inc. is headquartered in Minneapolis, Minnesota.
- 行业
- Medical - Devices
- 部门
- Healthcare
- 总部
- US
- 首席执行官
- Kevin Hykes
- 上市以来
- 2021年6月30日
- 雇员
- 223
市场位置
- 成交量
- 96.87万
- 1.67× 平均值
- 平均成交量
- 58.04万
- 日均成交量
- 市值
- 8106.73万 USD
- 贝塔
- 0.82
- 市场参考 1
CVRX同业公司
继续GoAI的研究
在 GoAI 中研究CVRXresearch.disclaimer





